Clinical study of different regimens of intravitreal injection of Conbercept in the treatment of SNPDR
Objective:To analyze the clinical effects of different regimens of intravitreal injection of Conbercept in the treatment of severe non-proliferative diabetic retinopathy(SNPDR).Methods:110 patients(110 eyes)with SNPDR from March 2021 to March 2022 were randomly divided into two groups.In 3+PRN group(55 cases,55 eyes),the patients were treated with on-demand therapy after three consecutive monthly injections of Conbercept into vitreous cavity.In the 5+PRN group(55 cases,55 eyes),the patients were treated with on-demand treatment after 5 consecutive monthly injections of Conbercept into vitreous cavity,and were followed up for 6 months.The best corrected visual acuity(BCVA),macular fovea thickness(CFT),microaneurysm(MA)and macular deep vascular density(DCPVD)were compared between the two groups before treatment,3 months after treatment and 6 months after treatment.Results:The number of injections in 5+PRN group was more than that in 3+PRN group(P<0.05).Six months after treatment,BCVA in 5+PRN group was higher than that in 3+PRN group,while CFT and MA in 5+PRN group were lower than those in 3+PRN group(P<0.05).There was no significant difference in DCPVD between the two groups at 3 and 6 months after treatment.Conclusion:The intravitreal injection of 3+PRN or 5+PRN with compatriot can both effectively treat SNPDR,but the 5+PRN regimen is more conducive to improving the patient's vision and fundus indicators after six months.
Severe non-proliferative diabetic retinopathyIntravitreal injectionConbercept
NETL
NSTL
万方数据
